Page 114 - ITPS-7-3

INNOSC Theranostics and
Pharmacological Sciences Alpha-2A receptor agonist and addiction

engages corticotropin-releasing factor and opioid systems to doi: 10.1016/j.mehy.2012.11.031
alter the operating mode of locus coeruleus norepinephrine 158. Vonck K, Raedt R, Naulaerts J, et al. Vagus nerve
neurons. Neuropharmacology. 2012;62(4):1737-1745.
stimulation…25 years later! What do we know about the
doi: 10.1016/j.neuropharm.2011.11.020 effects on cognition? Neurosci Biobehav Rev. 2014;45:63-71.
147. Guajardo HM, Snyder K, Ho A, Valentino RJ. Sex differences doi: 10.1016/j.neubiorev.2014.05.005
in μ-opioid receptor regulation of the rat locus coeruleus and 159. Berridge CW, Waterhouse BD. The locus coeruleus-
their cognitive consequences. Neuropsychopharmacology. noradrenergic system: Modulation of behavioral state and
2017;42(6):1295-1304.
state-dependent cognitive processes. Brain Res Brain Res
doi: 10.1038/npp.2016.252 Rev. 2003;42(1):33-84.
148. Brady KT, Randall CL. Gender differences in substance use doi: 10.1016/s0165-0173(03)00143-7
disorders. Psychiatr Clin North Am. 1999;22(2):241-252.
160. Kosten TA, Galloway MP, Duman RS, Russell DS, D’Sa C.
doi: 10.1016/s0193-953x(05)70074-5 Repeated unpredictable stress and antidepressants
differentially regulate expression of the bcl-2 family of
149. Srivastava AB, Gold MS. Naltrexone: A history and future
directions. Cerebrum. 2018;2018:cer-13-18. apoptotic genes in rat cortical, hippocampal, and limbic brain
structures. Neuropsychopharmacology. 2008;33(7):1545-1558.
150. Christie MJ. Cellular neuroadaptations to chronic opioids:
Tolerance, withdrawal and addiction. Br J Pharmacol. doi: 10.1038/sj.npp.1301527
2008;154(2):384-396. 161. Aston-Jones G, Chen S, Zhu Y, Oshinsky ML. A neural
circuit for circadian regulation of arousal. Nat Neurosci.
doi: 10.1038/bjp.2008.100
2001;4(7):732-738.
151. Gagne C, Moyse E, Kocher L, Bour H, Pujol JF. Light-
microscopic localization of somatostatin binding sites in the doi: 10.1038/89522
locus coeruleus of the rat. Brain Res. 1990;530(2):196-204. 162. Fang J, Rong P, Hong Y, et al. Transcutaneous vagus nerve
stimulation modulates default mode network in major
doi: 10.1016/0006-8993(90)91283-m
depressive disorder. Biol Psychiatry. 2016;79(4):266-273.
152. Williams JT, Christie MJ, Manzoni O. Cellular and synaptic
adaptations mediating opioid dependence. Physiol Rev. doi: 10.1016/j.biopsych.2015.03.025
2001;81(1):299-343. 163. Gold MS, Blum K, Febo M, et al. Molecular role of dopamine
in anhedonia linked to reward deficiency syndrome (RDS) and
doi: 10.1152/physrev.2001.81.1.299
anti- reward systems. Front Biosci (Schol Ed). 2018;10(2):309-325.
153. Lee JD, Nunes EV, Mpa PN, et al. NIDA clinical trials network doi: 10.2741/s518
CTN-0051, extended-release naltrexone vs. Buprenorphine
for opioid treatment (X: BOT): Study design and rationale. 164. Pallanti S, Bernardi S, Allen A, et al. Noradrenergic function
Contemp Clin Trials. 2016;50:253-264. in pathological gambling: blunted growth hormone response
to clonidine. J Psychopharmacol. 2010;24(6):847-853.
doi: 10.1016/j.cct.2016.08.004
doi: 10.1177/0269881108099419
154. Patterson Silver Wolf DA, Gold M. Treatment resistant
opioid use disorder (TROUD): Definition, rationale, and 165. Saddichha S, Vibha P, Vishnuvardhan G. Sapophagia
recommendations. J Neurol Sci. 2020;411:116718. (Compulsive Soap Eating) and attention-deficit/
hyperactivity disorder in a child responsive to clonidine.
doi: 10.1016/j.jns.2020.116718
J Clin Psychopharmacol. 2012;32(2):291.
155. Doughty B, Morgenson D, Brooks T. Lofexidine: A newly
FDA-approved, nonopioid treatment for opioid withdrawal. doi: 10.1097/JCP.0b013e3182499ad2
Ann Pharmacother. 2019;53(7):746-753. 166. Cazala P. Effect of clonidine and phentolamine on self-
stimulation behavior in the dorsal and ventral regions of the
doi: 10.1177/1060028019828954
lateral hypothalamus in mice. Psychopharmacology (Berl).
156. Clemow DB, Bushe CJ. Atomoxetine in patients with 1980;68(2):173-177.
ADHD: A clinical and pharmacological review of the
onset, trajectory, duration of response and implications for doi: 10.1007/BF00432137
patients. J Psychopharmacol. 2015;29(12):1221-1230. 167. Commissaris RL, Ellis DM, Hill TJ, Schefke DM, Becker CA,
Fontana DJ. Chronic antidepressant and clonidine treatment
doi: 10.1177/0269881115602489
effects on conflict behavior in the rat. Pharmacol Biochem
157. Fukada K, Endo T, Yokoe M, Hamasaki T, Hazama T, Behav. 1990;37(1):167-176.
Sakoda S. L-threo-3,4-dihydroxyphenylserine (L-DOPS)
co-administered with entacapone improves freezing of gait doi: 10.1016/0091-3057(90)90058-p
in Parkinson’s disease. Med Hypotheses. 2013;80(2):209-212. 168. Geller I, Blum K. The effects of 5-HTP on para-

Volume 7 Issue 3 (2024) 20 doi: 10.36922/itps.1918